Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Primary care clinicians' perspectives about quality measurements in safety-net clinics and non-safety-net clinics.

Culhane-Pera KA, Ortega LM, Thao MS, Pergament SL, Pattock AM, Ogawa LS, Scandrett M, Satin DJ.

Int J Equity Health. 2018 Nov 7;17(1):161. doi: 10.1186/s12939-018-0872-3.

2.

Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors.

London CA, Acquaviva J, Smith DL, Sequeira M, Ogawa LS, Gardner HL, Bernabe LF, Bear MD, Bechtel SA, Proia DA.

Clin Cancer Res. 2018 Dec 15;24(24):6396-6407. doi: 10.1158/1078-0432.CCR-18-0703. Epub 2018 Aug 31.

3.

A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer.

Gaponova AV, Nikonova AS, Deneka A, Kopp MC, Kudinov AE, Skobeleva N, Khazak V, Ogawa LS, Cai KQ, Duncan KE, Duncan JS, Egleston BL, Proia DA, Boumber Y, Golemis EA.

Clin Cancer Res. 2016 Oct 15;22(20):5120-5129. doi: 10.1158/1078-0432.CCR-15-3068. Epub 2016 Jun 7.

4.

HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.

Proia DA, Smith DL, Zhang J, Jimenez JP, Sang J, Ogawa LS, Sequeira M, Acquaviva J, He S, Zhang C, Khazak V, Astsaturov I, Inoue T, Tatsuta N, Osman S, Bates RC, Chimmanamada D, Ying W.

Mol Cancer Ther. 2015 Nov;14(11):2422-32. doi: 10.1158/1535-7163.MCT-15-0455. Epub 2015 Aug 13.

5.

UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib.

Landmann H, Proia DA, He S, Ogawa LS, Kramer F, Bei├čbarth T, Grade M, Gaedcke J, Ghadimi M, Moll U, Dobbelstein M.

Cell Death Dis. 2014 Sep 11;5:e1411. doi: 10.1038/cddis.2014.378.

6.

FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.

Acquaviva J, He S, Zhang C, Jimenez JP, Nagai M, Sang J, Sequeira M, Smith DL, Ogawa LS, Inoue T, Tatsuta N, Knowles MA, Bates RC, Proia DA.

Mol Cancer Res. 2014 Jul;12(7):1042-54. doi: 10.1158/1541-7786.MCR-14-0004. Epub 2014 Apr 30.

7.

A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors.

Zhou D, Liu Y, Ye J, Ying W, Ogawa LS, Inoue T, Tatsuta N, Wada Y, Koya K, Huang Q, Bates RC, Sonderfan AJ.

Toxicol Appl Pharmacol. 2013 Dec 1;273(2):401-9. doi: 10.1016/j.taap.2013.09.018. Epub 2013 Oct 1.

8.

Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.

Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, Zhou D, Inoue T, Tatsuta N, Sang J, Ye S, Acquaviva J, Ogawa LS, Wada Y, Barsoum J, Koya K.

Mol Cancer Ther. 2012 Feb;11(2):475-84. doi: 10.1158/1535-7163.MCT-11-0755. Epub 2011 Dec 5.

9.

Posterior synechia of the iris after combined pars plana vitrectomy, phacoemulsification, and intraocular lens implantation.

Shinoda K, O'hira A, Ishida S, Hoshide M, Ogawa LS, Ozawa Y, Nagasaki K, Inoue M, Katsura H.

Jpn J Ophthalmol. 2001 May-Jun;45(3):276-80.

PMID:
11369378

Supplemental Content

Loading ...
Support Center